Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.91 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940936 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5732904 | 0.95 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5732901 | 0.95 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5732737 | 0.87 | PTGER4 (0.84) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5732740 | 0.87 | PTGER4 (0.84) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5732735 | 0.87 | PTGER4 (0.84) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL14261762 | 0.85 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4941912 | 0.84 | PTGER4 (0.72) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4933370 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL14261761 | 0.82 | PTGER4 (0.91) | PTGER4PTGER2PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | claimed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | PTGER4 187/4885PTGER2 616/4885PTGER3 172/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | PTGER4 3/4885PTGER2 2/4885PTGER3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.